about
Acid ceramidase is upregulated in AML and represents a novel therapeutic target.Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemiaModification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.Cholecystokinin mediates progression and metastasis of pancreatic cancer associated with dietary fat.Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivoMaritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expressionGaucher's disease and cancer: a sphingolipid perspectiveReceptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin.PhotoImmunoNanoTherapy reveals an anticancer role for sphingosine kinase 2 and dihydrosphingosine-1-phosphateExtracts of Devil's club (Oplopanax horridus) exert therapeutic efficacy in experimental models of acute myeloid leukemia.Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia.Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches.Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer.Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia.Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinomaSphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia
P50
Q30275460-62C7170C-931A-4275-8F21-D4D4A71C2449Q30276873-C515E777-54E1-412D-8C19-87E3EDEF2181Q30300370-63B47B6C-80DD-498B-B448-B1F0B3D89E56Q33894658-E3E99F1B-6B05-4892-9A31-89C2BE39CEF1Q33951428-248F7BDE-832B-408E-865D-DA4DA12D3F21Q33989964-9CAE3DBD-CD9C-4F4B-AE92-5749CB8B2070Q34333982-60D166C2-730E-465C-BAC1-EAF42FAA7459Q35101294-9A892915-DB9F-42A3-8555-EB2001676950Q37131905-1DFB88CB-830F-4014-AA25-4729B8B0831DQ38945605-3C7B7C51-4925-43E2-A1CE-C6BCAB19F216Q39524122-CE4643A2-ACB0-4719-B35A-16C29F937C75Q39715843-CB4A3769-63F6-4A69-BEDF-F7381A112A5DQ39885402-475E5300-F8C1-4A6A-8922-B80383470DF2Q52559486-5D895ECB-57D6-4281-99D8-116FD1BCC86EQ83069706-8C797529-ED28-4073-B8AF-AC6C5E2E4D26Q93130849-4ADC7492-912B-49FB-BD9D-DECC243654E7
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Brian M Barth
@ast
Brian M Barth
@en
Brian M Barth
@es
Brian M Barth
@nl
type
label
Brian M Barth
@ast
Brian M Barth
@en
Brian M Barth
@es
Brian M Barth
@nl
prefLabel
Brian M Barth
@ast
Brian M Barth
@en
Brian M Barth
@es
Brian M Barth
@nl
P106
P1153
25721828500
P31
P496
0000-0002-3542-1804